Kristina Burow - 06 Jun 2023 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Reporting relationship: Director
Issuer ticker: BEAM
Reported as of: 06 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2023, 17:02:44 UTC
Prior SEC filing: 02 Sep 2022
Next SEC filing: 09 Jun 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Bellon, Attorney-in-fact

Key filing fact

Kristina Burow filed Form 4 for Beam Therapeutics Inc. (BEAM) on 08 Jun 2023.

Key facts

This page summarizes Kristina Burow's Form 4 filing for Beam Therapeutics Inc. (BEAM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2023, 17:02.

Change

Previous filing in this sequence was filed on 02 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BEAM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,721,520
Date: 06 Jun 2023
Ownership: See footnote
Footnotes: F1, F2

BEAM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,721,519
Date: 06 Jun 2023
Ownership: See footnote
Footnotes: F1, F3

BEAM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 26,011
Date: 06 Jun 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BEAM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,532
Change %
Price: $0.000000
Shares after: 16,532
Date: 06 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,532
Exercise price: $34.33
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Reflects change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person as a result of a distribution of Common Stock held by a limited partnership to its partners for no consideration.

Footnote F2

The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The reporting person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.

Footnote F3

The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The reporting person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The reporting person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.

Footnote F4

The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.